Location and incidence of chromosome and chromatid breaks in patients with Hodgkin's disease or testicular tumors.
In 90 patients aged 17 to 35 who suffered from Hodgkin's disease (HD) or had testicular tumors (TT), the location of chromosome and chromatid breaks on individual chromosome segments was reviewed using an adapted Funes-Cravioto scheme, in addition to examining the percentage of structural chromosomal aberrations. On the basis of an analysis of 1121 breaks in patients with HD or TT, the results were presented graphically as multiples of the expected number of breaks for the normal population. Before the beginning of treatment, the number of structural chromosomal aberrations (SCA) in patients with TT or HD was equal to that in a control group of subjects with malignant diseases. This, however, does not apply to the location of chromosome and chromatid breaks. In patients with HD, the dominant unstable sites are located on group A2 chromosomes, segments 2 and 5, and on group B chromosomes, segment 5. In patients with TT, the number of chromosome and chromatid breaks is also increased on group A2 chromosomes, segments 2 and 5, and in addition, also on group B chromosomes, segment 4.
Bilban-Jakopin
C
C
Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia. tinab@siol.com
Bilban
M
M
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002842:Chromatids / Q000235:genetics*; D002869:Chromosome Aberrations; D002874:Chromosome Mapping; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000235:genetics* / Q000628:therapy; D006801:Humans; D008297:Male; D009919:Orchiectomy; D018239:Seminoma / Q000473:pathology* / Q000628:therapy; D013736:Testicular Neoplasms / Q000235:genetics* / Q000628:therapy; D013997:Time Factors